Authors:
Adamson, PC
Widemann, BC
Reaman, GH
Seibel, NL
Murphy, RF
Gillespie, AF
Balis, FM
Citation: Pc. Adamson et al., A phase I trial and pharmacokinetic study of 9-cis-retinoic acid (ALRT1057) in pediatric patients with refractory cancer: A Joint Pediatric Oncology Branch, National Cancer Institute, and Children's Cancer Group Study, CLIN CANC R, 7(10), 2001, pp. 3034-3039
Authors:
Seibel, NL
Blaney, SM
O'Brien, M
Krailo, M
Hutchinson, R
Mosher, RB
Balis, FM
Gregory, H
Citation: Nl. Seibel et al., Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: A collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group trial, CLIN CANC R, 5(4), 1999, pp. 733-737
Authors:
Frangoul, H
Ames, MM
Mosher, RB
Reid, JM
Krailo, MD
Seibel, NL
Shaw, DWW
Steinherz, PG
Whitlock, JA
Holcenberg, JS
Citation: H. Frangoul et al., Phase I study of topotecan administered as a 21-day continuous infusion inchildren with recurrent solid tumors: A report from the Children's Cancer Group, CLIN CANC R, 5(12), 1999, pp. 3956-3962
Authors:
Arkin, S
Cooper, HA
Hutter, JJ
Miller, S
Schmidt, ML
Seibel, NL
Shapiro, A
Warrier, I
Citation: S. Arkin et al., Activated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patients with hemophilia A or B with inhibitors - Results of the NovoSeven emergency-use program, HAEMOSTASIS, 28(2), 1998, pp. 93-98